



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 13824

Title: Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe

Reviewer code: 02445675

Science editor: Ya-Juan Ma

Date sent for review: 2014-09-04 14:09

Date reviewed: 2014-09-27 01:15

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

I consider the paper suitable for publication on WJG.



ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 13824

Title: Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe

Reviewer code: 00004485

Science editor: Ya-Juan Ma

Date sent for review: 2014-09-04 14:09

Date reviewed: 2014-09-30 23:39

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This manuscript is limited by the unknown accuracy of the true incidence and prevalence of CD and CUC in Eastern and Central Europe. Nevertheless, it is an important paper in defining and trying to explain the variability of biologic use in IBD. 1. Please comment on the frequency of biologic use for IBD in 1) Western Europe, and 2) the US, relative to Central and Eastern Europe. 2. "Presenteeism," page 8, is not a word in the English language. Please rephrase. Nor is "originator" infliximab a commonly accepted term. The reviewer understands the reluctance to call this "Remicade" or its translation. One might define this as the "TNF inhibitor initially released" or the "originally released TNF monoclonal antibody," or... 3. There are multiple grammar suggestions that the reviewer has made to improve the flow of this manuscript. 4. Please clarify whether the costs quoted for the biologic medications are a per dose cost or for an induction/maintenance therapy. Either way, these costs are dramatically less than those charged in the US.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 13824

Title: Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe

Reviewer code: 02439579

Science editor: Ya-Juan Ma

Date sent for review: 2014-09-04 14:09

Date reviewed: 2014-10-09 15:51

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Many references are with the incidence of IBD decades ago, and some are not nationwide studies, the manuscript is limited by the unknown accuracy of the true incidence and prevalence of IBD in Eastern and Central Europe. Nevertheless, it is an important paper in trying to explain the variability of biologic use in IBD.